Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2019 11:07 ET | Source: ALK Abello

ALK opjusterer forventningerne til 2019 som følge af stærk vækst

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at virksomheden opjusterer forventningerne til regnskabsåret 2019 baseret på et bedre end forventet resultat for første halvår samt...
August 12, 2019 11:07 ET | Source: ALK Abello

ALK upgrades its full-year financial outlook due to strong growth

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the company has revised its 2019 financial guidance upwards based on the better than expected results in the first...
August 09, 2019 04:00 ET | Source: ALK Abello

ALK offentliggør ny anafylaksi-strategi baseret på nyt, innovativt produkt til USA

ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) nye anafylaksi-strategi er at blive en betydelig aktør på det amerikanske adrenalinmarked baseret på en eksklusivaftale med Windgap Medical om lancering af...
August 09, 2019 04:00 ET | Source: ALK Abello

ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA

ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) new anaphylaxis strategy is to become a major player in the US epinephrine market based on an exclusive deal with Windgap Medical to launch a next...
August 06, 2019 04:00 ET | Source: ALK Abello

Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2019 for ALK og webcast

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2019 tirsdag den 13. august 2019. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for...
August 06, 2019 04:00 ET | Source: ALK Abello

Release date of six-month interim report (Q2) 2019 for ALK and audio cast

On Tuesday, 13 August 2019, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its six-month interim report (Q2) 2019. ALK will host a meeting for analysts and institutional investors that day at...
June 24, 2019 03:00 ET | Source: ALK Abello

ALK submits registration application for tree SLIT-tablet in Canada

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Canadian regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for...
June 24, 2019 03:00 ET | Source: ALK Abello

ALK indsender registreringsansøgning for tabletvaccine mod træpollenallergi i Canada

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddeler i dag, at registreringsansøgningen for virksomhedens tabletvaccine mod træpollenallergi er accepteret til behandling af de canadiske...
June 07, 2019 08:57 ET | Source: ALK Abello

ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that it has successfully completed the marketing authorisation procedure for its tree sublingual allergy immunotherapy (SLIT) tablet in 17...
June 07, 2019 08:57 ET | Source: ALK Abello

ALK opnår europæisk godkendelse af tabletvaccinen mod allergisk rhinitis forårsaget af træpollen

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) har i dag meddelt, at godkendelsesproceduren for tabletvaccinen mod træpollenallergi (trætabletten) er succesfuldt afsluttet i 17 europæiske lande. Tabletten...